
Juan-Antonio Mico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1871516/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pain and depression comorbidity causes asymmetric plasticity in the locus coeruleus neurons. Brain, 2022, 145, 154-167.	7.6	29
2	Nerve injury induces transient locus coeruleus activation over time: role of the locus coeruleus–dorsal reticular nucleus pathway. Pain, 2022, 163, 943-954.	4.2	7
3	Reply to Cohen. Pain, 2022, 163, e607-e608.	4.2	0
4	Neuropathic pain increases spontaneous and noxious-evoked activity of locus coeruleus neurons. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110121.	4.8	16
5	The management of pediatric chronic pain in Spain: a web-based survey study. Current Medical Research and Opinion, 2021, 37, 303-310.	1.9	9
6	Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain, 2021, 162, 2629-2634.	4.2	205
7	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 164-176.	0.3	3
8	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 164-176.	1.8	13
9	Monoaminergic system and depression. Cell and Tissue Research, 2019, 377, 107-113.	2.9	101
10	CIBERSAM: Ten years of collaborative translational research in mental disorders. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 1-8.	0.3	5
11	Chemogenetic Silencing of the Locus Coeruleus–Basolateral Amygdala Pathway Abolishes Pain-Induced Anxiety and Enhanced Aversive Learning in Rats. Biological Psychiatry, 2019, 85, 1021-1035.	1.3	64
12	Monoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Pain. Frontiers in Neuroscience, 2019, 13, 1268.	2.8	50
13	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 1-8.	1.8	68
14	Opioid Activity in the Locus Coeruleus Is Modulated by Chronic Neuropathic Pain. Molecular Neurobiology, 2019, 56, 4135-4150.	4.0	16
15	Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain. Neuropharmacology, 2018, 135, 202-210.	4.1	7
16	Behavioral effects of combined morphine and MK-801 administration to the locus coeruleus of a rat neuropathic pain model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 84, 257-266.	4.8	20
17	Factors Influencing Cognitive Impairment in Neuropathic and Musculoskeletal Pain and Fibromyalgia. Pain Medicine, 2018, 19, 499-510.	1.9	31
18	Effect of Deep Brain Stimulation of the ventromedial prefrontal cortex on the noradrenergic system in rats. Brain Stimulation, 2018, 11, 222-230.	1.6	26

#	Article	IF	CITATIONS
19	Understanding the different relationships between mood and sleep disorders in several groups of non-oncological patients with chronic pain. Current Medical Research and Opinion, 2018, 34, 669-676.	1.9	7
20	Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats. European Journal of Pain, 2018, 22, 127-141.	2.8	21
21	Reply. Pain, 2018, 159, 1177-1178.	4.2	3
22	Prevalence of central and peripheral neuropathic pain in patients attending pain clinics in Spain: factors related to intensity of pain and quality of life. Journal of Pain Research, 2018, Volume 11, 1835-1847.	2.0	10
23	The complex association between the antioxidant defense system and clinical status in early psychosis. PLoS ONE, 2018, 13, e0194685.	2.5	8
24	The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain. Pain, 2018, 159, 2606-2619.	4.2	14
25	Deep brain stimulation electrode insertion and depression: Patterns of activity and modulation by analgesics. Brain Stimulation, 2018, 11, 1348-1355.	1.6	11
26	Reply. Pain, 2017, 158, 1396-1396.	4.2	0
27	Discovery and development of tramadol for the treatment of pain. Expert Opinion on Drug Discovery, 2017, 12, 1281-1291.	5.0	106
28	Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2623-2632.	3.3	35
29	Reply. Pain, 2017, 158, 180-180.	4.2	3
30	Activation of Extracellular Signal-Regulated Kinases (ERK 1/2) in the Locus Coeruleus Contributes to Pain-Related Anxiety in Arthritic Male Rats. International Journal of Neuropsychopharmacology, 2017, 20, 463-463.	2.1	17
31	Deep Brain Stimulation: A Promising Therapeutic Approach to the Treatment of Severe Depressed Patients — Current Evidence and Intrinsic Mechanisms. , 2017, , 251-264.		0
32	Assessing the Construct Validity and Internal Reliability of the Screening Tool Test Your Memory in Patients with Chronic Pain. PLoS ONE, 2016, 11, e0154240.	2.5	9
33	A review of chronic pain impact on patients, their social environment and the health care system. Journal of Pain Research, 2016, Volume 9, 457-467.	2.0	569
34	Do we need a third mechanistic descriptor for chronic pain states?. Pain, 2016, 157, 1382-1386.	4.2	502
35	Use and satisfaction with the Healthcare System of the chronic pain patients in Spain: results from a nationwide study. Current Medical Research and Opinion, 2016, 32, 1813-1820.	1.9	12
36	Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?. European Journal of Pain, 2016, 20, 472-482.	2.8	28

#	Article	IF	CITATIONS
37	The Atypical Antipsychotic Paliperidone Regulates Endogenous Antioxidant/Anti-Inflammatory Pathways in Rat Models of Acute and Chronic Restraint Stress. Neurotherapeutics, 2016, 13, 833-843.	4.4	38
38	Effect of DSP4 and desipramine in the sensorial and affective component of neuropathic pain in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 57-67.	4.8	16
39	Reply. Pain, 2016, 157, 2876-2877.	4.2	2
40	Noradrenergic Locus Coeruleus pathways in pain modulation. Neuroscience, 2016, 338, 93-113.	2.3	154
41	Comorbid anxiety-like behavior and locus coeruleus impairment in diabetic peripheral neuropathy: A comparative study with the chronic constriction injury model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 45-56.	4.8	30
42	Stress Increases the Negative Effects of Chronic Pain on Hippocampal Neurogenesis. Anesthesia and Analgesia, 2015, 121, 1078-1088.	2.2	30
43	Pro-/Antiinflammatory Dysregulation in Early Psychosis: Results from a 1-Year Follow-Up Study. International Journal of Neuropsychopharmacology, 2015, 18, pyu037-pyu037.	2.1	26
44	Corticotropin-Releasing Factor Mediates Pain-Induced Anxiety through the ERK1/2 Signaling Cascade in Locus Coeruleus Neurons. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	14
45	Desarrollo profesional en investigación traslacional en neurociencias y salud mental: educación y formación dentro del Centro de Investigación Biomédica en Red en Salud Mental. Revista De PsiquiatrÃa Y Salud Mental, 2015, 8, 65-74.	1.8	6
46	ERK1/2: Function, signaling and implication in pain and pain-related anxio-depressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 60, 77-92.	4.8	33
47	A Nationwide Study of Chronic Pain Prevalence in the General Spanish Population: Identifying Clinical Subgroups Through Cluster Analysis. Pain Medicine, 2015, 16, 811-822.	1.9	68
48	Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia. Schizophrenia Bulletin, 2014, 40, 376-387.	4.3	156
49	Glycine <i>N</i> â€methyltransferase expression in the hippocampus and its role in neurogenesis and cognitive performance. Hippocampus, 2014, 24, 840-852.	1.9	26
50	Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Pain, 2014, 155, 2171-2179.	4.2	109
51	Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. Schizophrenia Research, 2014, 156, 23-29.	2.0	42
52	Pain exacerbates chronic mild stress-induced changes in noradrenergic transmission in rats. European Neuropsychopharmacology, 2014, 24, 996-1003.	0.7	38
53	Fluoxetine: a case history of its discovery and preclinical development. Expert Opinion on Drug Discovery, 2014, 9, 567-578.	5.0	116
54	Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Molecular Psychiatry, 2014, 19, 607-614.	7.9	63

#	Article	IF	CITATIONS
55	Reversal of Monoarthritis-induced Affective Disorders by Diclofenac in Rats. Anesthesiology, 2014, 120, 1476-1490.	2.5	35
56	The impact of chronic pain: The perspective of patients, relatives, and caregivers Families, Systems and Health, 2014, 32, 399-407.	0.6	39
57	Stress-Induced Neuroinflammation: Role of the Toll-Like Receptor-4 Pathway. Biological Psychiatry, 2013, 73, 32-43.	1.3	169
58	Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. Translational Psychiatry, 2013, 3, e221-e221.	4.8	26
59	Social stress exacerbates the aversion to painful experiences in rats exposed to chronic pain: The role of the locus coeruleus. Pain, 2013, 154, 2014-2023.	4.2	42
60	Chronic Pain Leads to Concomitant Noradrenergic Impairment and Mood Disorders. Biological Psychiatry, 2013, 73, 54-62.	1.3	149
61	Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. International Journal of Neuropsychopharmacology, 2013, 16, 151-162.	2.1	72
62	Undiagnosed Mood Disorders and Sleep Disturbances in Primary Care Patients with Chronic Musculoskeletal Pain. Pain Medicine, 2013, 14, 1416-1425.	1.9	36
63	Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophrenia Research, 2012, 137, 58-65.	2.0	50
64	Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophrenia Research, 2012, 137, 66-72.	2.0	96
65	Elucidating the Mechanism of Action of Pregabalin. CNS Drugs, 2012, 26, 637-648.	5.9	50
66	Preclinical discovery of duloxetine for the treatment of depression . Expert Opinion on Drug Discovery, 2012, 7, 745-755.	5.0	9
67	Antioxidant defense system and family environment in adolescents with family history of psychosis. BMC Psychiatry, 2012, 12, 200.	2.6	5
68	Depressive-like States Heighten the Aversion to Painful Stimuli in a Rat Model of Comorbid Chronic Pain and Depression. Anesthesiology, 2012, 117, 613-625.	2.5	87
69	Analgesic antidepressants promote the responsiveness of locus coeruleus neurons to noxious stimulation: Implications for neuropathic pain. Pain, 2012, 153, 1438-1449.	4.2	47
70	Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall–Selitto model. Behavioural Pharmacology, 2011, 22, 599-606.	1.7	9
71	Pain as a symptom of depression: Prevalence and clinical correlates in patients attending psychiatric clinics. Journal of Affective Disorders, 2011, 130, 106-112.	4.1	104
72	Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. European Journal of Pharmacology, 2011, 655, 46-51.	3.5	48

#	Article	IF	CITATIONS
73	Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry, 2011, 11, 26.	2.6	94
74	Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice. Journal of Pharmacy and Pharmacology, 2010, 52, 659-663.	2.4	3
75	Medically unexplained pain complaints are associated with underlying unrecognized mood disorders in primary care. BMC Family Practice, 2010, 11, 17.	2.9	45
76	Effectiveness of repeated administration of a new oral naltrexone controlled-release system on morphine analgesia. Journal of Pharmacy and Pharmacology, 2010, 53, 1201-1205.	2.4	2
77	Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. International Journal of Neuropsychopharmacology, 2009, 12, 1033.	2.1	40
78	Opiates as Antidepressants. Current Pharmaceutical Design, 2009, 15, 1612-1622.	1.9	109
79	In Vivo Effect of Venlafaxine on Locus Coeruleus Neurons: Role of Opioid, α2-Adrenergic, and 5-Hydroxytryptamine1A Receptors. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 101-107.	2.5	25
80	In vivo effect of tramadol on locus coeruleus neurons is mediated by α2-adrenoceptors and modulated by serotonin. Neuropharmacology, 2006, 51, 146-153.	4.1	30
81	Antidepressants and pain. Trends in Pharmacological Sciences, 2006, 27, 348-354.	8.7	371
82	The Role of 5-HT1A Receptors in Research Strategy for Extensive Pain Treatment. Current Topics in Medicinal Chemistry, 2006, 6, 1997-2003.	2.1	46
83	Role of 5-HT1A and 5-HT1B receptors in the antinociceptive effect of tramadol. European Journal of Pharmacology, 2005, 511, 21-26.	3.5	35
84	Effectiveness and tolerability of the buprenorphinetransdermal system in patients with moderate to severe chronic pain: A multicenter, open-label, uncontrolled, prospective, observational clinical study. Clinical Therapeutics, 2005, 27, 451-462.	2.5	47
85	Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain. Psychopharmacology, 2004, 176, 305-311.	3.1	14
86	The role of age in the development of Schneiderian symptoms in patients with a first psychotic episode. Acta Psychiatrica Scandinavica, 2004, 109, 264-268.	4.5	18
87	Antidepressant-Like Effect of tramadol and its Enantiomers in Reserpinized Mice: Comparativestudy with Desipramine, Fluvoxamine, Venlafaxine and Opiates. Journal of Psychopharmacology, 2004, 18, 404-411.	4.0	52
88	Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neuroscience Letters, 2004, 363, 25-28.	2.1	36
89	Age-dependence of Schneiderian psychotic symptoms in bipolar patients. Schizophrenia Research, 2003, 61, 157-162.	2.0	37
90	Interactions of acute morphine with chronic imipramine and fluvoxamine treatment on the antinociceptive effect in arthritic rats. Neuroscience Letters, 2003, 352, 37-40.	2.1	9

#	Article	IF	CITATIONS
91	Antinociceptive effects of tricyclic antidepressants and their noradrenergic metabolites. European Neuropsychopharmacology, 2003, 13, 355-363.	0.7	28
92	The Role of 5-HT1A/BAutoreceptors in the Antinociceptive Effect of Systemic Administration of Acetaminophen. Anesthesiology, 2003, 98, 741-747.	2.5	21
93	Efficacy and Safety of Venlafaxine-ECT Combination in Treatment-Resistant Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 206-209.	1.8	29
94	Treatment of Bipolar I Rapid Cycling Patients During Dysphoric Mania with Olanzapine. Journal of Clinical Psychopharmacology, 2002, 22, 450-454.	1.4	35
95	Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sciences, 2002, 72, 143-152.	4.3	108
96	Mania and Tramadol-Fluoxetine Combination. American Journal of Psychiatry, 2001, 158, 964-a-965.	7.2	32
97	Venlafaxine for the Treatment of Neuropathic Pain. Journal of Pain and Symptom Management, 2000, 19, 408-410.	1.2	33
98	Pindolol, a beta-adrenoceptor blocker/5-hydroxytryptamine1A/1B antagonist, enhances the analgesic effect of tramadol. Pain, 2000, 88, 119-124.	4.2	37
99	Involvement of δ-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. European Journal of Pharmacology, 1998, 354, 1-7.	3.5	91
100	Antinociception produced by the peptidase inhibitor, RB 101, in rats with adrenal medullary transplant into the spinal cord. European Journal of Pharmacology, 1998, 356, 139-148.	3.5	3
101	Tramadol induces antidepressant-type effects in mice. Life Sciences, 1998, 63, PL175-PL180.	4.3	91
102	The Effects of Different Monoaminergic Antidepressants on the Analgesia Induced by Spinal Cord Adrenal Medullary Transplants in the Formalin Test in Rats. Anesthesia and Analgesia, 1997, 84, 816-820.	2.2	19
103	Implication of β1- and β2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants. European Neuropsychopharmacology, 1997, 7, 139-145.	0.7	30
104	Attenuation of learned helplessness in rats after transplant of adrenal medulla into the spinal cord. European Psychiatry, 1996, 11, 249-253.	0.2	4
105	Effect on nociception of intracerebroventricular administration of low doses of neuropefitde y in mice. Life Sciences, 1996, 58, 2409-2414.	4.3	19
106	Preclinical study of a controlled release oral morphine system in rats. International Journal of Pharmaceutics, 1996, 139, 237-241.	5.2	9
107	Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacology Biochemistry and Behavior, 1995, 52, 145-152.	2.9	110
108	Study of the mechanisms involved in behavioral changes induced by flunitrazepam in morphine withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 973-991.	4.8	9

#	Article	IF	CITATIONS
109	Effect of neonatal handling on learned helplessness model of depression. Physiology and Behavior, 1995, 57, 407-410.	2.1	46
110	Influence of antidepressant drugs administration on the morphine inhibitory effect in mice vasa deferentia. Life Sciences, 1995, 57, PL339-PL345.	4.3	0
111	Effect of Amitriptyline on the Analgesia Induced by Adrenal Medullary Tissue Transplanted in the Rat Spinal Subarachnoid Space as Measured by an Experimental Model of Acute Pain. Experimental Neurology, 1994, 130, 9-14.	4.1	21
112	Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 1073-1092.	4.8	79
113	Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biological Psychiatry, 1993, 34, 100-107.	1.3	42
114	Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice. Drug and Alcohol Dependence, 1992, 30, 293-300.	3.2	14
115	Influence of different benzodiazepines on the experimental morphine abstinence syndrome. Psychopharmacology, 1991, 105, 197-203.	3.1	27
116	Long-term administration of fluvoxamine antagonizes the inhibitory effect of neuropeptide Y but not the clonidine effect on isolated rat vas deferens. European Journal of Pharmacology, 1990, 183, 497-498.	3.5	0
117	RB 38 B, a selective neutral endopeptidase inhibitor, induced reversal off escape deficits caused by inescapable shocks pretreatment in rats. European Journal of Pharmacology, 1990, 183, 2317-2318.	3.5	7
118	The influence of several contaminants of street narcotics on experimental morphine withdrawal syndrome. European Journal of Pharmacology, 1990, 183, 1436-1437.	3.5	0
119	Evaluation of the analgesic effect of fluvoxamine on experimental acute and chronic pain. European Journal of Pharmacology, 1990, 183, 1446-1447.	3.5	3
120	Central administration of neuropeptide y induces hypothermia in mice. Possible interaction with central noradrenergic systems. Life Sciences, 1989, 45, 2395-2400.	4.3	25
121	Comparative study in mice of flunitrazepam vs. diazepam on morphine withdrawal syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 927-933.	4.8	16
122	Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology, 1987, 26, 531-539.	4.1	77
123	The automated tail suspension test: A computerized device which differentiates psychotropic drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1987, 11, IN1-671.	4.8	187
124	Comparative Study in Mice of Ten 1,4â€Benzodiazepines and of Clobazam: Anticonvulsant, Anxiolytic, Sedative, and Myorelaxant Effects. Epilepsia, 1986, 27, S14-7.	5.1	29
125	Antinociceptive activity of beta-adrenoceptor agonists in the hot plate test in mice. Psychopharmacology, 1986, 88, 527-8.	3.1	20